drugset / Trial / NCT00148681
Preoperative Herceptin and Navelbine for Breast Cancer
Phase 2
Completed
49 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
Timeline
- Start
- 2001-05
- Primary completion
- 2003-05
- Completion
- 2003-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Navelbine | Unknown | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |